PARIS, Oct. 15 /PRNewswire-FirstCall/ -- Cellectis (Alternext: ALCLS), the French genome engineering specialist, today published its consolidated financial statement for the half-year ending June 30, 2010: revenues increased 25% over H1 2009, expenditure increased 50% and the company ended the period with euro 38 million in cash reserves.
During the first half of 2010, Cellectis entered into a number of important new agreements (with BASF Plant Science, Boehringer Ingelheim), published data in a peer-reviewed journal on the therapeutic potential of meganucleases in Duchenne muscular dystrophy and launched Cellectis plant sciences. Cellectis was also granted the INPI National Innovation Award for its intellectual property strategy. In addition, Cellectis' research and production tools subsidiary, Cellectis bioresearch, entered into a development and commercial manufacturing agreement with Lonza that establishes a presence for Cellectis in the bioproduction market.
"The figures for this half year reflect our growth strategy," said Andre Choulika, CEO at Cellectis. "Cellectis' staff has doubled in a year and comprises 130 people today, in all entities, compared to 65 in July 2009. This has allowed us to strengthen our position, in all aspects of our business, with highly competent and committed people."
"The capital increase that was made in October 2009 allows us to finance this rapid growth and support our ambitious external growth strategy," added Marc Le Bozec, CFO at Cellectis.
The slide show presenting the half-year results in details is available on http://www.cellectis.com/investors/accounts-and-reports
Simplified Income Statement – Financial items are presented according to IFRS | ||||
Figures in thousands of euros | 2010 | 2009 | ||
Sales | 6 250 | 5 020 | ||
Other revenue | 63 | 36 | ||
Total revenue | 6 313 | 5 056 | ||
Consumables | (1 231) | (901) | ||
Wages & Salaries | (4 502) | (2 908) | ||
Other operating expenses | (9 276) | (6 752) | ||
Tax | (168) | (193) | ||
Depreciation & Amortization | (139) | (221) | ||
Total operating expenses | (15 316) | (10 975) | ||
Current operating income/loss | (9 003) | (5 919) | ||
Other non-current income and expenses | 46 | 61 | ||
Operating income (loss) | (8 957) | (5 858) | ||
Financial income | 241 | 282 | ||
Financial expenses | (17) | (1) | ||
Cost of financing, net | 225 | 281 | ||
Income tax | 5 240 | 2 810 | ||
Net operating income (loss) | (3 492) | (2 767) | ||
About Cellectis
Cellectis is a pioneer in the field of genome engineering. The company designs and markets innovative tools -meganucleases. These molecular scissors enable targeted modifications to DNA, with applications in the research, biomanufacturing, agrobiotechnology and therapeutic sectors.
To date, Cellectis has formed over 20 academic research partnerships and has established more than 50 agreements with pharmaceutical laboratories, seed producers and biotech companies across the world. The company holds exclusive rights to a portfolio of over 260 patents granted or pending.
Since 2007, Cellectis has been listed on the NYSE-Euronext Alternext market (code: ALCLS) in Paris and has secured over euro 70 million in funding since inception.
More information at www.cellectis.com
Follow Cellectis on Twitter at www.twitter.com/cellectis
Disclaimer
This press release and the information contained herein do not constitute an offer to sell or subscribe, or a solicitation of an offer to buy or subscribe, for shares in Cellectis in any country. This press release contains forward-looking statements that relate to the Company's objectives. Such forward-looking statements are based on the current expectations and assumptions of the Company's management only and involve risk and uncertainties. Potential risks and uncertainties include, without limitation, whether the Company will be successful in implementing its strategies, whether there will be continued growth in the relevant market and demand for the Company's products, new products or technological developments introduced by competitors, and risks associated with managing growth. Unfavorable developments in connection with these and other risks and uncertainties described, in particular, in the Company's prospectus prepared in connection with its IPO and on which the French Autorite des marches financiers ("AMF") granted its visa no. 07-023 on January 22, 2007, could cause the Company to fail to achieve the objectives expressed by the forward-looking statements above.
SOURCE Cellectis
